Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Jun, 2017 | Pages:
44 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1) - Pipeline Review, H1 2017 Summary Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1) - Leucine-rich repeat kinase 2 (LRRK2) is an enzyme encoded by the PARK8 gene. It plays a role in the retrograde trafficking pathway for recycling proteins, such as mannose 6 phosphate receptor (M6PR), between lysosomes and the Golgi apparatus in a retromer-dependent manner together with RAB29. It regulates neuronal process morphology in the intact central nervous system. Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1) pipeline Target constitutes close to 16 molecules. Out of which approximately 13 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Preclinical and Discovery stages are 8 and 5 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 1 and 2 molecules, respectively. Report covers products from therapy areas Central Nervous System, Ophthalmology and Respiratory which include indications Parkinson's Disease, Neurodegenerative Diseases, Glaucoma and Lung Disease. The latest report Leucine Rich Repeat SerineThreonine Protein Kinase 2 - Pipeline Review, H1 2017, outlays comprehensive information on the Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1) targeted therapeutics development with respective active and dormant or discontinued projects. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape for Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1) - The report reviews Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1) targeted therapeutics and enlists all their major and minor projects - The report assesses Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news and deals related to Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1) targeted therapeutics Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand the targeted therapy areas and indications for Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1) - Identify the use of drugs for target identification and drug repurposing - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1) development landscape - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
List of Tables List of Figures Introduction Global Markets Direct Report Coverage Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1) - Overview Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1) - Therapeutics Development Products under Development by Stage of Development Products under Development by Therapy Area Products under Development by Indication Products under Development by Companies Products under Development by Universities/Institutes Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1) - Therapeutics Assessment Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1) - Companies Involved in Therapeutics Development Arrien Pharmaceuticals LLC D. Western Therapeutics Institute Inc Denali Therapeutics Inc H. Lundbeck A/S Lead Discovery Center GmbH Merck & Co Inc Novartis AG Oncodesign SA Origenis GmbH Pfizer Inc Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1) - Drug Profiles GNE-7915 - Drug Profile Product Description Mechanism Of Action R&D Progress H-1337 - Drug Profile Product Description Mechanism Of Action R&D Progress ODS-2005294 - Drug Profile Product Description Mechanism Of Action R&D Progress ORS-1104 - Drug Profile Product Description Mechanism Of Action R&D Progress PF-06447475 - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecule to Inhibit LRRK2 for Parkinson's Disease - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecules to Inhibit LRRK-2 for Parkinson's Disease - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecules to Inhibit LRRK-2 for Parkinson's Disease - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecules to Inhibit LRRK2 for Neurodegenerative Diseases - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecules to Inhibit LRRK2 for Neurodegenerative Diseases and Parkinson's Disease - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecules to Inhibit LRRK2 for Parkinson's Disease - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecules to Inhibit LRRK2 for Parkinson's Disease - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecules to Inhibit LRRK2 for Parkinson's Disease - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecules to Inhibit LRRK2 for Parkinson's Disease - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecules to Inhibit LRRK2 for Parkinson's Disease - Drug Profile Product Description Mechanism Of Action R&D Progress SR-9444 - Drug Profile Product Description Mechanism Of Action R&D Progress Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1) - Dormant Products Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1) - Product Development Milestones Featured News & Press Releases May 23, 2017: Origenis Announces Patent Grants for Lead Small Molecule LRRK2 Inhibitors for Treatment of Neurodegenerative and Inflammatory Diseases May 30, 2016: Oncodesign is granted new patent protecting key molecules generated from its Nanocyclix technology platform for next generation kinase inhibitors Oct 21, 2015: Oncodesign Presents Novel LRRK2 Inhibitor Jointly Discovered with Ipsen at the 2015 Neurosciences Meeting in Chicago Sep 09, 2014: Arrien Pharmaceuticals announced that the U.S. Patent and Trademark Office has issued U.S. Patents No. 8,791,112 B2 Aug 16, 2012: Arrien Pharma's ORS-1104 Advances Into Investigational New Drug Enabling Stage May 05, 2012: Arrien Pharma Provides Update on ORS-1104 for Treatment of Parkinson's Disease Appendix Methodology Coverage Secondary Research Primary Research Expert Panel Validation Contact Us Disclaimer
List of Tables
Number of Products under Development by Stage of Development, H1 2017 Number of Products under Development by Therapy Areas, H1 2017 Number of Products under Development by Indication, H1 2017 Number of Products under Development by Companies, H1 2017 Products under Development by Companies, H1 2017 Number of Products under Investigation by Universities/Institutes, H1 2017 Products under Investigation by Universities/Institutes, H1 2017 Number of Products by Stage and Mechanism of Actions, H1 2017 Number of Products by Stage and Route of Administration, H1 2017 Number of Products by Stage and Molecule Type, H1 2017 Pipeline by Arrien Pharmaceuticals LLC, H1 2017 Pipeline by D. Western Therapeutics Institute Inc, H1 2017 Pipeline by Denali Therapeutics Inc, H1 2017 Pipeline by H. Lundbeck A/S, H1 2017 Pipeline by Lead Discovery Center GmbH, H1 2017 Pipeline by Merck & Co Inc, H1 2017 Pipeline by Novartis AG, H1 2017 Pipeline by Oncodesign SA, H1 2017 Pipeline by Origenis GmbH, H1 2017 Pipeline by Pfizer Inc, H1 2017 Dormant Projects, H1 2017
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
